On the contrary, histone deacetylase (HDAC) inhibitors, especially pan-HDAC inhibitors (Dacinostat, Panobinostat, and more than other 100 compounds) and the class I HDAC inhibitor romidepsin were effective regardless of IDH mutation status and chondrosarcoma subtype [129]. This evidence concerns the gene IDH1 and chondrosarcoma.